Kopran

KOPRAN26 Apr 2024

Pharmaceuticals

₹

-5.10 (-1.96%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Kopran

Kopran

Pharmaceuticals

KOPRAN26 Apr 2024

₹

-5.10 (-1.96%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date	Ratio
25-May-2023	D	Dividend for the FY 2022-23 At the said meeting, the Board has Recommended dividend of Rs.3/- per Equity Share of F.V Rs.10 (@ 30%) to the shareholders for the year ended March 31, 2023.	07-Sep-2023
27-May-2022	D	Kopran Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 27, 2022, inter alia, has recommended dividend of Rs. 3.00 per Equity Share of F.V Rs. 10 (30%) to the Members of the Company for declaration at the forthcoming 63rd Annual General Meeting. The dividend recommended as above, if declared by the Members of the Company at the forthcoming 63rd Annual General Meeting, shall be paid, subject to deduction of tax at source as applicable, on or before 30 days from the date of the Annual General Meeting.	04-Aug-2022
27-May-2021	D	Kopran Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 27, 2021, inter alia, has recommended a Final dividend of Rs. 1.50 (15%) per equity share of Rs. 10 each for the year ended March 31, 2021 subject to approval of members at the 62nd AGM. Earlier an interim dividend of Rs. 1.50 (15%) per equity share was paid in the month of November, 2020.	05-Aug-2021
28-Oct-2020	D	Kopran Ltd has informed BSE that the Board of Directors of the Company at its meeting held on October 28, 2020, inter alia, has declared interim dividend of Rs. 1.50/- per equity share of face value of Rs. 10/- each for the financial year 2020-21.	05-Nov-2020
28-Feb-2002	R	One equity share of Rs.10/- each at a premium of Rs.30/- per share on rights basis for every two existing equity shares held. Kopran Ltd. has informed the Exchange that the BoD have decided to extend the closure of Rights issue from June 07 2002 to June 22, 2002. (71,50,000 equity shares of Rs.10 each, for cash at a premium of Rs.30 per share, aggregating to Rs.2860 lacs, on a rights basis in the ratio of one equity share for every two equity shares held as on record date i.e. March 28, 2002.) [NSE dated 07.06.2002]	28-Mar-2002	1:2
23-Jan-2024	BC	KOPRAN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2024 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Res	07-Feb-2024
26-Oct-2023	BC	KOPRAN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2023 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Res	07-Nov-2023
17-Aug-2023	BC	AGM 14/09/2023 64th Annual General Meeting will be held on September 14, 2023 (As Per BSE Announcement Dated on: 16/08/2023) Annual report 2022-23 (As Per BSE Announcement Dated on 25/08/	14-Sep-2023
15-Sep-2023	BC	Outcome, Proceeding and Voting Results of 64th Annual General Meeting for the FY 2022-23 along with Scrutinizer Report	14-Sep-2023
17-Aug-2023	BC	Rs.3.0000 per share(30%)Dividend & A.G.M	08-Sep-2023

Record Date01 Jan'1900

Ex-Rights Date01 Jan'1900

Premium(Rs.)30

Ratio1:2

Book Closure

Record Date	Split Date	Purpose
07-Feb-2024	-	KOPRAN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2024 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Res
07-Nov-2023	-	KOPRAN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2023 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Res
14-Sep-2023	-	AGM 14/09/2023 64th Annual General Meeting will be held on September 14, 2023 (As Per BSE Announcement Dated on: 16/08/2023) Annual report 2022-23 (As Per BSE Announcement Dated on 25/08/
14-Sep-2023	-	Outcome, Proceeding and Voting Results of 64th Annual General Meeting for the FY 2022-23 along with Scrutinizer Report
08-Sep-2023	01 Jan'1900	Rs.3.0000 per share(30%)Dividend & A.G.M

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Kopran Ltd ₹254.90(-5.10/-1.96%)	254.90	-5.10	1,228.89	64.50	49.50	3.14
Astrazeneca Pharma India Ltd ₹5,415.40(+81.55/1.53%)	5,415.40	+81.55	13,538.50	71.09	84.88	20.67
Bliss GVS Pharma Ltd ₹122.60(+5.85/5.01%)	122.60	+5.85	1,283.51	60.79	18.80	1.31
Cipla Ltd ₹1,409.40(+4.00/0.28%)	1,409.40	+4.00	113,794.25	54.54	34.60	4.40
Abbott India Ltd ₹25,864.85(+201.35/0.78%)	25,864.85	+201.35	54,962.81	15.87	47.98	17.68
Amrutanjan Health Care Ltd ₹680.85(-8.80/-1.28%)	680.85	-8.80	1,968.38	13.21	44.73	7.51

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	82.33	98.64	65.86	80.23	67.96	53.62
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	82.33	98.64	65.86	80.23	67.96	53.62
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	1.29	5.79	1.48	2.07	1.16	14.74
Total Income	83.62	104.43	67.34	82.30	69.12	68.36
Total Expenditure	70.27	89.94	65.04	72.86	61.86	47.72
PBIDT	13.35	14.49	2.30	9.44	7.26	20.64
Interest	1.02	0.74	0.95	0.84	0.72	0.61
PBDT	12.33	13.75	1.35	8.60	6.54	20.03
Depreciation	1.17	1.16	1.12	1.09	1.12	1.12
Tax	2.80	1.93	0.13	1.97	1.33	1.19
Deferred Tax	-0.15	-0.01	-0.06	0.02	0.05	-0.17
Reported Profit After Tax	8.51	10.66	0.15	5.52	4.04	17.89
Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	8.51	10.66	0.15	5.52	4.04	17.89

EPS (Unit Curr.)	1.77	2.21	0.03	1.14	0.84	3.71
EPS (Adj) (Unit Curr.)	1.77	2.21	0.03	1.14	0.84	3.71
Calculated EPS (Unit Curr.)	1.77	2.21	0.03	1.14	0.84	3.71
Calculated EPS (Adj) (Unit Curr.)	1.77	2.21	0.03	1.14	0.84	3.71
Calculated EPS (Ann.) (Unit Curr.)	7.06	8.85	0.13	4.58	3.36	14.84
Calculated EPS (Adj) (Ann.) (Unit Curr.)	7.06	8.85	0.13	4.58	3.36	14.84
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	48.21	48.21	48.21	48.21	48.21	48.21
Reserve & Surplus	0.00	0.00	0.00	0.00	0.00	0.00
Face Value	10.00	10.00	10.00	10.00	10.00	10.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	16.22	14.69	3.49	11.77	10.68	38.49
PBDTM(%)	14.98	13.94	2.05	10.72	9.62	37.36
PATM(%)	10.34	10.81	0.23	6.88	5.94	33.36

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	158.92	152.59	117.00	148.88	158.00	116.97
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	158.92	152.59	117.00	148.88	158.00	116.97
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	2.43	0.13	2.39	3.78	2.22	0.44
Total Income	161.35	152.72	119.39	152.66	160.22	117.40
Total Expenditure	135.34	129.76	110.69	136.72	145.68	106.83
PBIDT	26.01	22.96	8.70	15.94	14.54	10.58
Interest	2.24	1.94	1.83	1.78	2.24	1.28
PBDT	23.77	21.02	6.87	14.16	12.30	9.30
Depreciation	3.27	2.77	3.26	3.24	3.16	3.25
Minority Interest Before NP	0.00	0.00	0.00	0.00	0.00	0.00
Tax	4.70	4.09	0.62	2.41	2.04	1.28
Deferred Tax	0.02	0.39	0.21	0.47	0.15	0.12
Reported Profit After Tax	15.79	13.77	2.77	8.04	6.95	4.65
Minority Interest After NP	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit after Minority Interest	15.79	13.77	2.77	8.04	6.95	4.65

Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	15.79	13.77	2.77	8.04	6.95	4.65

EPS (Unit Curr.)	3.28	2.86	0.58	1.67	1.44	0.97
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	48.21	48.21	48.21	48.21	48.21	48.21

Public Shareholding (Number)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (%)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	16.37	15.05	7.44	10.71	9.20	9.05
PBDTM(%)	14.96	13.78	5.87	9.51	7.78	7.95
PATM(%)	9.94	9.02	2.37	5.40	4.40	3.98

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	48.21	48.21	43.25	43.25	48.83	51.83
Reserves Total	347.38	330.51	203.60	186.42	175.19	162.50
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	395.59	378.72	246.85	229.67	224.02	214.33
Secured Loans	25.88	26.82	12.72	14.40	18.77	23.13
Unsecured Loans	2.00	10.08	3.00	31.32	25.64	20.42
Total Debt	27.88	36.90	15.72	45.72	44.41	43.55
Total Liabilities	423.47	415.62	262.57	275.39	268.43	257.88
APPLICATION OF FUNDS :
Gross Block	73.17	67.63	64.60	56.00	51.46	44.71
Less : Accumulated Depreciation	25.82	21.41	17.16	13.05	9.58	6.56
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	47.35	46.22	47.44	42.95	41.88	38.15
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	3.53	3.10	2.82	7.07	6.75	7.84
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	260.07	259.43	158.79	158.14	157.52	156.92
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	47.60	41.51	27.50	41.17	25.19	29.75
Sundry Debtors	83.81	59.13	49.46	42.48	44.59	20.13
Cash and Bank	2.59	2.55	3.22	1.15	1.05	1.53
Loans and Advances	56.40	48.11	30.92	29.44	36.60	40.50
Total Current Assets	190.41	151.31	111.11	114.24	107.43	91.91
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	74.55	40.66	54.58	47.15	45.52	38.27
Provisions	0.74	0.77	0.64	0.67	1.01	1.41
Total Current Liabilities	75.29	41.42	55.21	47.82	46.52	39.69
Net Current Assets	115.12	109.88	55.90	66.42	60.90	52.22
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	1.40	1.33	2.40	5.87	7.19	8.98
Deferred Tax Liability	4.25	4.36	4.71	4.64	4.24	5.22
Net Deferred Tax	-2.85	-3.03	-2.31	1.23	2.95	3.76
Total Assets	423.22	415.60	262.64	275.81	270.01	258.89
Contingent Liabilities	47.77	45.45	50.50	85.48	78.91	83.93

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	48.21	48.21	43.25	43.25	48.83	51.83
Reserves Total	391.04	377.96	201.78	146.43	125.23	101.46
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	439.25	426.17	245.03	189.68	174.06	153.29
Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00
Secured Loans	57.98	55.64	61.33	62.88	61.70	51.77
Unsecured Loans	17.26	18.91	4.98	25.40	29.66	28.48
Total Debt	75.24	74.55	66.31	88.28	91.36	80.25
Policy Holders Fund	0.00	0.00	0.00	0.00	0.00	0.00
Other Liabilities	8.51	8.09	7.47	7.20	6.42	5.14
Total Liabilities	523.00	508.81	318.81	285.16	271.84	238.68
APPLICATION OF FUNDS :
Gross Block	233.83	206.81	157.31	146.31	138.14	121.27
Less: Accumulated Depreciation	68.84	56.12	45.12	35.16	25.52	16.84
Less: Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	164.99	150.69	112.19	111.15	112.62	104.43
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	69.58	35.55	42.89	30.24	24.29	9.93
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.06	0.06	0.05	0.02	0.02	0.05
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	130.61	149.94	100.00	88.50	73.45	71.01
Sundry Debtors	162.56	127.36	120.08	92.81	86.64	64.77
Cash and Bank	12.58	57.13	6.90	4.75	3.96	6.18
Loans and Advances	93.32	80.44	49.97	36.55	43.52	51.54
Total Current Assets	399.07	414.88	276.95	222.61	207.56	193.49
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	118.40	91.63	112.76	82.70	76.03	75.17
Provisions	1.23	4.17	2.84	0.91	2.87	1.45
Total Current Liabilities	119.63	95.80	115.60	83.61	78.90	76.62
Net Current Assets	279.44	319.08	161.36	138.99	128.67	116.87
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	2.70	2.54	3.46	6.86	9.16	11.83
Deferred Tax Liability	9.78	8.82	8.45	8.31	7.80	8.21
Net Deferred Tax	-7.08	-6.28	-4.99	-1.45	1.36	3.62
Other Assets	16.00	9.72	7.30	6.20	4.86	3.78
Total Assets
Contingent Liabilities	19.87	40.74	21.08	121.78	115.71	121.22

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019
Cash and Cash Equivalents at Beginning of the year	0.25	0.32	0.21	0.21	0.27
Net Cash from Operating Activities	16.87	-37.80	48.77	9.97	11.84
Net Cash Used In Investing Activities	10.05	-100.26	-8.51	0.63	-4.47
Net Cash Used In Financing Activities	-26.13	137.99	-40.14	-10.60	-7.43
Net Inc./Dec In Cash And Cash Equivalents	0.79	-0.07	0.12	0.00	-0.06
Cash And Cash Equivalents At End Of The Year	1.04	0.25	0.32	0.21	0.21

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

44.49%

FII Shareholding

0.84%

DII Shareholding

1.20%

Public Shareholding

53.47%

**Promoter pledged shareholding 44.49%

About Kopran Ltd

Kopran Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 1228.89 crores. It has reported a sales of Rs. 82.33 crores and a net profit of Rs. 8.51 crores for the quarter ended December 2018. The company management includes Susheel Somani, Surendra Somani,Sunil Sodhani,Siddhan Subramanian,Sunita Banerji,Mamta Biyani,Narayan Atal,Susheel Somani,Adarsh Somani,Varun Somani (Kopran Ltd) among others.

Chairman

Susheel Somani

Registered office

Parijat House 1076,Dr E Moses Road Worli,Mumbai,Maharashtra,400018

FAX :91-22-24950363

Background

Incorporation Year1958

Face Value₹10

Market Lot1

How to buy Kopran shares on nse?

To buy Kopran shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Kopran share price today?

The Kopran shares price on nse is Rs.254.9 today.

What is the market cap of Kopran shares on BSE ?

The company has a market capitalization of Rs.1228.89Cr

What is the PE & PB ratio of Kopran shares ?

PE is 49.5 and PB is 3.14

What is the 52 Week High and Low of Kopran shares?

Kopran stock price high: Rs.292.4 Kopran stock price low: Rs.140